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a b s t r a c t 
Tenosynovial giant cell tumors are extremely rare tumors with highly nonspecific symp- 
toms. This benign but aggressive disease has a slow course of progression; however, it can 
ultimately lead to irreversible damage to a joint. Here we describe a case of a 45-year-old 
female with a diagnosis of tenosynovial giant cell tumors of the distal tibiofibular joint, the 
second case described in the literature for such location. Appropriate imaging studies and 
ultimately histologic studies are necessary for the correct diagnosis. Some locations are par- 
ticularly unusual for these tumors making a high level of suspicion as well as treatment by 
an oncology orthopedic surgery specialist at a high-volume center paramount. 
© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
Tenosynovial giant cell tumors (TGCT) were fist described in 
1941 by Jaffe and include a group of tumors present usually 
in relationship with synovium, bursas or tendon sheaths [1] . 
In 2013 the World Health Organization re-named this dis- 
ease from what was formerly being called extra-articular gi- 
ant cell tumor of tendon sheath and nodular tenosynovitis to 
localized TGCT, while what was initially called intra-articular 
pigmented villonodular synovitis was-renamed diffuse TGCT 
and includes the diffuse-type giant cell tumors [2] . This dis- 
ease affects most commonly adults between the third and 
fourth decade of life but has been known to affect the pe- 
diatric population as well [3 ,4] . Additionally, TGCT demon- 
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strates a slight predominance for females (60%) [3] . TGCT is 
in the vast majority of the cases a monoarticular disease al- 
though multijoint affectation has been reported; moreover, 
as previously mentioned it can present as a localized nod- 
ule or diffusely affecting a joint [5 ,6] . The prevalence of TGCT 
is thought to be of 1.8 cases per million for the diffuse form 
and 9.2 per million for the localized form [7] . The localized 
form of this disease affects more commonly the hands and 
digits, followed by foot and ankle, while the diffuse form in- 
volves mainly the knee, followed in frequency by hip, ankle, 
and elbow [2 ,8] . Symptoms are nonspecific which along the 
rarity of this disease can cause a significant delay in the di- 
agnosis of these patients [9] . Because this is a slow progress- 
ing disease time from initial symptoms to the final histo- 
logic diagnosis can vary from a year to 3 years [10] . Patients 
https://doi.org/10.1016/j.radcr.2021.01.064 
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Fig. 1 – Positron emission tomography with computed 
tomography. Axial images demonstrating uptake at the 
level of the distal tibiofibular joint ( ∗) with a standard 
uptake value of 7.9 as well as scalloping of the distal lateral 
tibia (arrowhead). 
can present with pain, swelling and limitation of the affected 
joint as well as repeated episodes of hemarthrosis over time 
[9 ,11] . 
Here we describe a case of TGCT of the distal tibiofibular 
joint, an extremely rare location, managed by surgical resec- 
tion. To the best of our knowledge this is the second localized 
case in such location to be described in literature. 
Case report 
A 45-year-old female with history of costochondritis, fibrocys- 
tic breasts, hypercholesterolemia, and gastroesophageal re- 
flux disease, was referred to our orthopedic oncology clinic 
for further evaluation and management of a left ankle le- 
Fig. 2 – Magnetic resonance imaging study from August 2020 depicting the lesion in the distal tibiofibular joint ( ∗), the distal 
lateral scalloping and posterior invasion into the soft tissues (arrowhead). (A) proton density sequency of 2 axial cuts view 
and 1 sagittal, (B) T1 fat suppressed with Gadolinium sequence, 2 axial cuts and 1 sagittal view, (C) short tau inversion 
recovery sequence, 2 axial cuts and 1 sagittal cut. 
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Fig. 3 – Fluoroscopic images used for guidance during the 
biopsy mini-open procedure. A pituitary instrument is 
observed within the distal tibiofibular joint. 
sion found on recent imaging studies. During the initial visit, 
the patient reported left ankle pain which was new and had 
been present for 2 months. Patient stated the pain was mod- 
erated and controlled by nonsteroidal anti-inflammatories. 
Due to her pain, she was unable to exercise and required 
the use of a cane for assistance with ambulation. In addi- 
tion, patient reported recent fatigue. She denied night sweats, 
chills, fever, unintentional weight loss, and loss of appetite. 
On physical examination, no palpable mass, tenderness, ery- 
thema, or swelling over the left ankle were noted. Range 
of motion and sensation in the ankle were within normal 
limits. 
Prior to initial consultation, the patient obtained several 
diagnostic imaging studies due to a new mass noted on her 
breast. A positron emission tomography with computed to- 
mography scan was obtained (July 2020) and revealed a le- 
sion in the distal tibiofibular joint with fluorodeoxyglucose up- 
take and a maximum standardized uptake value of 7.9 ( Fig. 1 ). 
A decision was made to obtain a contrasted magnetic res- 
onance imaging (MRI) study. The MRI of the left ankle with 
and without Gadolinium contrast obtained in August 2020 
demonstrated an enhancing 2.2 × 1.8 × 3.5 cm soft tissue 
mass at the syndesmosis space corresponding to the area of 
hyper-metabolic activity on the positron emission tomogra- 
phy with computed tomography scan ( Fig. 2 ). Small foci of 
T1/T2 hypo-intense signal within the mass, a possible reflec- 
tion of mineralization, was also reported. In addition, the MRI 
reported an area of cortical scalloping over the distal lateral 
tibia suggesting a chronic nonaggressive process with no ab- 
normal marrow signal or other evidence of osseous infiltra- 
tion, however overall characteristics of the mass were inde- 
terminate and tissue sampling was recommended to exclude 
malignancy. 
It was decided to proceed with an open biopsy of the left 
ankle mass under fluoroscopic guidance ( Fig. 3 ). A 3 cm in- 
cision was made over the distal posterior aspect of the left 
lateral malleolus. Dissection was carried down to bone with a 
cautery. The fibular tendon and muscle were retracted medi- 
ally and the posterior aspect of the tibiofibular joint visualized. 
A mass with yellowish and brown components was then ob- 
served, and samples were obtained for frozen and permanent 
pathology analysis ( Fig. 4 ). Pathology report revealed a diagno- 
sis of giant cell tumor of tendon sheath. 
Patient was taken to the operating room 3 weeks later for 
left ankle tumor resection under fluoroscopic guidance. A 4 
cm incision was done over the prior incision over the distal 
posterior aspect of the left malleolus. Deep dissection was 
carried down bluntly. The fibularis tendons were retracted 
distally and the posterior aspect of the tibiofibular joint was 
accessed. The TGCT was identified, marginally resected, and 
sent to pathology for analysis. Pathology report revealed mass 
to be synovial tissue with nodular hyperplasia with pigment 
deposition consistent with TGCT ( Fig. 5 ). 
Patient is currently 3 months post tumor resection with 
completely resolution of her ankle symptoms. Patient was rec- 
ommended physical therapy and will continue surveillance 
studies with a new contrasted MRI in 6 months. 
Discussion 
TGCT are a group of benign tumors and although the disease 
tends to be slow growing it can potentially damage a joint 
and severely affect the quality of life of these patients [9 ,10] . 
The disease usually presents in young adults with highly 
nonspecific symptoms which leads to the diagnosis often- 
times being delayed for years. The etiology of this disease 
is not known though the mechanism by which it damages 
the joints has been identified [12 ,13] . There is an uncontrol- 
lable proliferation of the synovium (villonodular proliferation), 
hemosiderin deposits which causes the pigmentation seen in 
our mass ( Fig. 4 ), the tumor cells attract an inflammatory in- 
filtrate with mononuclear and multinuclear osteoclast-giant 
cells that along with the repetitive episodes of hemarthrosis 
are thought to be responsible for the joint damage [14 ,15] . 
On radiographs this disease can present as a joint effusion 
as well as bone erosion; with rare but described calcifications 
within the tumor [16 ,17] . The bone lesions present a sclerotic 
margin and are usually present in both sides of the joint [16] . 
As with most tumors the preferred imaging study is an MRI 
with and without contrast. There TGCT is depicted as a lo- 
calized or diffuse mass with heterogeneous low signal inten- 
sity on T1 and T2-sequences that enhances with Gadolinium. 
Blooming effect is also usually observed due to the magnetic 
effect the iron within the hemosiderin deposits causes [18] . 
Some areas with low hemosiderin concentration can also dis- 
play a high intensity on T1 and T2 sequences, but the classi- 
cal image is the one of a mass low in T1 and T2 sequences 
[18] . More recently PET-CT scans have also been used to study 
TGCT and also to assess treatment effect when a systemic 
modality of treatment is chosen [19] . TGCT lesions present 
with significant uptake and can have a mean standardized up- 
take value of 8.7 behaving as hypermetabolic tumors, a char- 
acteristic that can mislead radiologists towards a malignant 
diagnosis such as sarcoma or metastatic disease [20 ,21] . 
On histopathology analysis TGCT present as a combina- 
tion in variable proportions of small histiocytes, mononuclear 
cells with eccentrical nuclei, eosinophilic cytoplasm, and a pe- 
ripheral rim of hemosiderin, osteoclasts-like giant cells, xan- 
thomatous (foamy) macrophages, lymphocytes, and plasma 
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Fig. 4 – Gross image of the sample obtained for pathology analysis during the biopsy. A mass with yellowish and brown 
areas is seen. (Color version of figure is available online.) 
Fig. 5 – Histopathological analysis of the left ankle mass resection. (A) low power view of the mass depicting sheets of cells 
of infiltrative nature and a dense stroma (H&E, 10x), (B) Dense small mononuclear cell stroma (H&E, 10x), (C) Mononuclear 
cell stroma and osteoclast-like multinucleated giant cells (H&E, 20x), (D) Giant cells in more detail, histocytes and foam cells 
(H&E, 20x). 
cells [22] . Due to this common facade of an inflammatory in- 
filtrate, there was an initial thought that there was an inflam- 
matory component to the nature of this disease, leading some 
to claim it was an inflammatory process such as rheumatoid 
arthritis, but a clonal mutation was identified which allowed 
to confirm the tumoral nature of this lesion [23 ,24] . A spe- 
cific translocation involving chromosomes 1 and 2, causing 
the overexpression of colony-stimulating factor 1 (CSF1) was 
identified in 2006 as critical for development of this disease 
[24] . The augmented CSF1 expression is only found in 2%-16% 
of the cells, the remaining cells being the nonspecific inflam- 
matory infiltrate previously described. These inflammatory 
cells are attracted due to a receptor that responds to the over- 
expressed factor (CSF1R) [24] . Currently available treatment 
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options target this receptor to address TGCT, when resection 
is not indicated [25] . 
Treatment for TGCT is predominantly surgical, with exci- 
sion of the tumor. Depending on the location and the extent 
of disease, the procedure may be done open or arthroscopi- 
cally. The rate of recurrence for this disease is high, 14%-40%, 
which causes patients to undergo several surgical procedures, 
future joint replacements, decreased range of motion and low 
quality of life [26 ,27] . Radiation therapy has been advocated as 
an option to decrease recurrence in diffuse TGCT however is 
not free of complications such as joint stiffness, osteoarthri- 
tis, osteonecrosis, and malignant transformation or secondary 
radiation induced sarcomas [28] . 
Conclusion 
TGCT are benign but aggressive soft tissue tumors with highly 
nonspecific symptoms at presentation. Some locations such 
as the distal tibiofibular joint are particularly unusual and a 
high level of suspicion as well as the correct imaging studies 
are paramount for the correct diagnosis of this rare disease as 
it could be confused with a degenerative cyst. These tumors 
although slow growing have the potential to irreversibly dam- 
age a joint, making appropriate diagnosis and treatment by an 
oncology orthopedic surgery specialist at a high-volume cen- 
ter of the utmost importance. 
Patient Consent 
Per the local Institutional Review Board consent was exempt 
due to this being the case of research involving the collec- 
tion or study of existing data, documents, records, patholog- 
ical specimens, or diagnostic specimen with the information 
being recorded by the investigator in such a manner that sub- 
jects cannot be identified, directly or through identifiers linked 
to the subjects. 
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